1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Genufood Energy Enzymes Corp.

Genufood Energy Enzymes Corp.

GFOO
Genufood Energy Enzymes Corp.US flagOther OTC
0.00
USD
- -
- -
80,890.00Market Cap
Genufood Energy Enzymes Corp.
GFOO
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2018
2019
2020
2021
2022
2023
TTM
FRC
0.04
0.02
0.01
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.17
-0.11
-0.43
- -
- -
- -
-0.01
- -
- -
- -
Basic EPS, GAAP
-0.07
-0.14
-0.44
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.05
-0.15
-0.57
-0.01
-0.11
-0.09
-0.04
-0.03
-0.02
-0.01
Book Value per Share
0.17
0.3
0.23
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
3
4
4
64
70
92
215
300
526
697
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-416.67
-723.14
-4,064.28
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
- -
-2
- -
- -
- -
-1
- -
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-418.37
-725.91
-4,081.22
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
1
1
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
1
1
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
809
809
809
Market Capitalization
11
1
4

Working Capital

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-60.96%
-164.45%
Free Cash Flow
- -
11.01%
67.16%
Net Income, GAAP
- -
70.49%
77.99%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Thayer Ventures Acquisition Corporation II Rights (TVAIR)
Investcorp India Acquisition Corp (IVCAW)
SIM Acquisition Corp. I (SIMAW)
Global System Dynamics, Inc. (GSDWW)
Pontem Corporation (PNTM-UN)
Warburg Pincus Capital Corporation I-B (WPCBF)
Business
Genufood Energy Enzymes Corp. Genufood Energy Enzymes Corp. (GFOO) engages in promoting, marketing, distributing, and exporting a range of enzyme products manufactured in the United States for human and animal consumption, primarily targeting markets in Asia including the Association of Southeast Asian Nations (ASEAN); the company also focuses on building, owning, and operating electric vehicle charging stations across the United States, with operations spanning the southwestern region and beyond. Founded on June 21, 2010, and headquartered at 1108 S. Baldwin Avenue, Suite 107, Arcadia, California 91007, Genufood Energy Enzymes Corp. operates as a development-stage entity in the health technology and pharmaceuticals sector, led by key executives including CEO David Tang, President and Chairman Jui Pin Lin, and CFO Kuang Ming Tsai. Core offerings encompass specialized enzyme catalysts for nutritional and therapeutic applications in humans and livestock, alongside emerging infrastructure for EV charging solutions to support sustainable transportation. Recent strategic shifts include a transition from primary enzyme export activities to EV charging station development, positioning the company as a shell entity pursuing diversification in the electric utilities space amid evolving market demands.